Editorial comment

摘要

There is no question that the advancement of robotic and laparoscopic techniques has contributed to the dominance of minimally invasive surgery for prostate cancer. Minimally invasive radical prostatectomy (MIRP) was adopted rapidly, before large population-based studies could be performed. We sought to explore a unique dataset with comprehensive data on complications and mortality that encompasses the contemporary time period over which MIRP has been adopted. Although the National Surgical Quality Improvement Program cannot provide data on oncologic outcomes, it is highly accurate in predicting postoperative morbidity and mortality. The next step is to validate the long-term oncologic efficacy and morbidity of MIRP for prostate cancer.